Cargando…

Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity

BACKGROUND: Anthracycline-induced cardiotoxicity is a well-known serious clinical entity. However, detailed mechanistic insights on how short-term administration leads to late and long-lasting cardiotoxicity, are still largely undiscovered. We hypothesize that chemotherapy provokes a memory effect a...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Emma L., Ameri, Pietro, Delrue, Leen, Vanderheyden, Marc, Bartunek, Jozef, Altieri, Paola, Heymans, Stephane, Heggermont, Ward A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034031/
https://www.ncbi.nlm.nih.gov/pubmed/36970338
http://dx.doi.org/10.3389/fcvm.2023.884174
_version_ 1784911119834415104
author Robinson, Emma L.
Ameri, Pietro
Delrue, Leen
Vanderheyden, Marc
Bartunek, Jozef
Altieri, Paola
Heymans, Stephane
Heggermont, Ward A.
author_facet Robinson, Emma L.
Ameri, Pietro
Delrue, Leen
Vanderheyden, Marc
Bartunek, Jozef
Altieri, Paola
Heymans, Stephane
Heggermont, Ward A.
author_sort Robinson, Emma L.
collection PubMed
description BACKGROUND: Anthracycline-induced cardiotoxicity is a well-known serious clinical entity. However, detailed mechanistic insights on how short-term administration leads to late and long-lasting cardiotoxicity, are still largely undiscovered. We hypothesize that chemotherapy provokes a memory effect at the level of epigenomic DNA modifications which subsequently lead to cardiotoxicity even years after cessation of chemotherapy. METHODS: We explored the temporal evolution of epigenetic modifiers in early and late cardiotoxicity due to anthracyclines by means of RNA-sequencing of human endomyocardial left ventricular biopsies and mass spectrometry of genomic DNA. Based on these findings, validation of differentially regulated genes was obtained by performing RT-qPCR. Finally, a proof-of-concept in vitro mechanistic study was performed to dissect some of the mechanistic aspects of epigenetic memory in anthracycline-induced cardiotoxicity. RESULTS: Correlation of gene expression between late and early onset cardiotoxicity revealed an R(2) value of 0.98, demonstrating a total of 369 differentially expressed genes (DEGs, FDR < 0.05). of which 72% (n = 266) were upregulated, and 28% of genes, (n = 103) downregulated in later as compared to earlier onset cardiotoxicity. Gene ontology analysis showed significant enrichment of genes involved in methyl-CpG DNA binding, chromatin remodeling and regulation of transcription and positive regulation of apoptosis. Differential mRNA expression of genes involved in DNA methylation metabolism were confirmed by RT-qPCR in endomyocardial biopsies. In a larger biopsy cohort, it was shown that Tet2 was more abundantly expressed in cardiotoxicity biopsies vs. control biopsies and vs. non-ischemic cardiomyopathy patients. Moreover, an in vitro study was performed: following short-term doxorubicin treatment, H9c2 cells were cultured and passaged once they reached a confluency of 70%–80%. When compared to vehicle-only treated cells, in doxorubicin-treated cells, three weeks after short term treatment, Nppa, Nppb, Tet1/2 and other genes involved in active DNA demethylation were markedly upregulated. These alterations coincided with a loss of DNA methylation and a gain in hydroxymethylation, reflecting the epigenetic changes seen in the endomyocardial biopsies. CONCLUSIONS: Short-term administration of anthracyclines provokes long-lasting epigenetic modifications in cardiomyocytes both in vivo and in vitro, which explain in part the time lapse between the use of chemotherapy and the development of cardiotoxicity and, eventually, heart failure.
format Online
Article
Text
id pubmed-10034031
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100340312023-03-24 Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity Robinson, Emma L. Ameri, Pietro Delrue, Leen Vanderheyden, Marc Bartunek, Jozef Altieri, Paola Heymans, Stephane Heggermont, Ward A. Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Anthracycline-induced cardiotoxicity is a well-known serious clinical entity. However, detailed mechanistic insights on how short-term administration leads to late and long-lasting cardiotoxicity, are still largely undiscovered. We hypothesize that chemotherapy provokes a memory effect at the level of epigenomic DNA modifications which subsequently lead to cardiotoxicity even years after cessation of chemotherapy. METHODS: We explored the temporal evolution of epigenetic modifiers in early and late cardiotoxicity due to anthracyclines by means of RNA-sequencing of human endomyocardial left ventricular biopsies and mass spectrometry of genomic DNA. Based on these findings, validation of differentially regulated genes was obtained by performing RT-qPCR. Finally, a proof-of-concept in vitro mechanistic study was performed to dissect some of the mechanistic aspects of epigenetic memory in anthracycline-induced cardiotoxicity. RESULTS: Correlation of gene expression between late and early onset cardiotoxicity revealed an R(2) value of 0.98, demonstrating a total of 369 differentially expressed genes (DEGs, FDR < 0.05). of which 72% (n = 266) were upregulated, and 28% of genes, (n = 103) downregulated in later as compared to earlier onset cardiotoxicity. Gene ontology analysis showed significant enrichment of genes involved in methyl-CpG DNA binding, chromatin remodeling and regulation of transcription and positive regulation of apoptosis. Differential mRNA expression of genes involved in DNA methylation metabolism were confirmed by RT-qPCR in endomyocardial biopsies. In a larger biopsy cohort, it was shown that Tet2 was more abundantly expressed in cardiotoxicity biopsies vs. control biopsies and vs. non-ischemic cardiomyopathy patients. Moreover, an in vitro study was performed: following short-term doxorubicin treatment, H9c2 cells were cultured and passaged once they reached a confluency of 70%–80%. When compared to vehicle-only treated cells, in doxorubicin-treated cells, three weeks after short term treatment, Nppa, Nppb, Tet1/2 and other genes involved in active DNA demethylation were markedly upregulated. These alterations coincided with a loss of DNA methylation and a gain in hydroxymethylation, reflecting the epigenetic changes seen in the endomyocardial biopsies. CONCLUSIONS: Short-term administration of anthracyclines provokes long-lasting epigenetic modifications in cardiomyocytes both in vivo and in vitro, which explain in part the time lapse between the use of chemotherapy and the development of cardiotoxicity and, eventually, heart failure. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10034031/ /pubmed/36970338 http://dx.doi.org/10.3389/fcvm.2023.884174 Text en © 2023 Robinson, Ameri, Delrue, Vanderheyden, Bartunek, Altieri, Heymans and Heggermont. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Robinson, Emma L.
Ameri, Pietro
Delrue, Leen
Vanderheyden, Marc
Bartunek, Jozef
Altieri, Paola
Heymans, Stephane
Heggermont, Ward A.
Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title_full Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title_fullStr Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title_full_unstemmed Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title_short Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
title_sort differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals dna methylation as a key regulator of cardiotoxicity
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034031/
https://www.ncbi.nlm.nih.gov/pubmed/36970338
http://dx.doi.org/10.3389/fcvm.2023.884174
work_keys_str_mv AT robinsonemmal differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT ameripietro differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT delrueleen differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT vanderheydenmarc differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT bartunekjozef differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT altieripaola differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT heymansstephane differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity
AT heggermontwarda differentialexpressionofepigeneticmodifiersinearlyandlatecardiotoxicheartfailurerevealsdnamethylationasakeyregulatorofcardiotoxicity